53 results about "Endometriosis" patented technology

The invention provides a stem cell composition for treating endometrial repair. Specifically, the invention also provides an oligopeptide ZGC-5 which can significantly inhibit ectopic endometrial cell proliferation and has therapeutic activity, and the oligopeptide has the effects of inhibiting ectopic endometrial cell proliferation and promoting apoptosis. After the oligopeptide and the stem cells are prepared into the medicine box, the medicine box has a good effect of treating endometriosis.

The invention relates to the technical field of biomedical treatment, in particular to bifidobacterium longum subsp. Longum and application thereof in drugs related to reproductive system diseases. The invention provides a strain of Bifidobacterium longum subsp. Longum NCU-06, which is preserved in China General Microbiological Culture Collection Center (CGMCC), the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, the preservation date is January 18, 2023, and the preservation number is CGMCC No.26491. The invention also provides a method for preparing the Bifidobacterium longum subsp. Longum NCU-06. The bifidobacterium longum subsp. Longum NCU-06 has a treatment effect on various female reproductive system diseases, for example, the bifidobacterium longum subsp. Longum NCU-06 can be used for treating endometriosis, ovarian cancer, ovarian cancer parneoplastic thrombocythemia and ovarian hyperstimulation syndrome.

The invention discloses an application of dasatinib in preparation of a medicine for treating endometriosis. The dasatinib can be used for treating endometriosis. The new application of the dasatinib in treating the endometriosis has important clinical significance on accurate treatment of the endometriosis.

The present invention relates to a gonadotropin-releasing hormone antagonist, which has an antagonistic activity against gonadotropin-releasing hormone and can be used for the prevention or treatment of a sex hormone-dependent disease, such as benign prostatic hypertrophy, hysteromyoma, endometriosis, metrofibroma, precocious puberty, amenorrhea, premenstrual syndrome, or dysmenorrhea, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and a pharmaceutical composition comprising the same.

The invention belongs to the technical field of medicines, and provides a preparation technology of a sterile injection of rerugolix, which comprises the following steps: redissolving freeze-dried powder consisting of raw material medicines and auxiliary materials by using sterile water for injection, slowly releasing the rerugolix within 2-8 weeks, maintaining the dynamic balance of blood concentration, and preparing the sterile injection of the rerugolix by using the freeze-dried powder to prepare the sterile injection of the rerugolix. Release of gonadotropin is effectively controlled, and the pharmaceutical composition is used for treating indications such as prostatic cancer, uterine fibroma and endometriosis.

The present invention covers furoindazole compounds of general formula (I): in which R1, R2, R3, R4, R5, R6a and R6b are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type I and type II, and polycystic ovary syndrome (PCOS) disorders, neuropathic and inflammatory pain disorders in humans and animals.

The invention discloses a full-cycle management method for an endometriosis patient, and relates to the technical field of medical informatization decision making, and the method comprises the steps: collecting the preliminary diagnosis disease staging information, lesion feature text and laboratory inspection data of the patient, and generating a case data set through medical term standardized conversion and text structured processing; constructing a recurrence risk prediction model, inputting the case data set into the recurrence risk prediction model, and generating a recurrence risk quantitative score; adjusting a follow-up period based on the recurrence risk quantitative score, setting follow-up time nodes and medical examination items, and combining to generate a follow-up plan; and performing graded reminding based on the follow-up visit plan, and collecting symptom scoring records, medicine use data and life quality evaluation results submitted by the patient to form a follow-up visit data set. The dynamic follow-up visit plan is generated by constructing the recurrence risk prediction model, individualized follow-up visit management is achieved, and the problem that follow-up visit depends on static experience and cannot be matched with a real risk level is solved.

A method for treating a non-cancerous gynecological condition, the method comprising administering to a patient an effective amount of a composition comprising a cannabis extract comprising cannabidiol (CBD) wherein the composition is preferably administered in mucosal form, such as intravaginal.

A method of detecting the presence or absence of endometriosis is provided herein that includes exposing a biological chemosensory array to a test volatile organic compound (VOC) mixture, obtaining a test neuronal response, comparing the test neuronal response to a control response, and outputting a result based on the comparison. A system for detecting the presence or absence of endometriosis is also provided herein, which includes an odor stimulus delivery component for delivering a test VOC mixture to a biological chemosensory array, a neuron probe for detecting a test neuronal response, and a processor for storing the test neuronal response.

The invention relates to the technical field of medicine, and particularly discloses an endometriosis prescription for dysmenorrhea with endometriosis. Comprising the following raw materials: 10-15 parts of radix salviae miltiorrhizae, 7-10 parts of rhizoma curcumae, 2-3 parts of flos carthami, 7-10 parts of vinegar turtle shell, 10-15 parts of salted radix achyranthis bidentatae, 7-10 parts of rhizoma corydalis, 10-15 parts of prepared fingered citron, 5-8 parts of radix bupleuri, 10-15 parts of radix paeoniae alba, 10-15 parts of caulis spatholobi, 10-15 parts of poria cocos, 7-10 parts of herba taxilli, 7-10 parts of radix dipsaci, 3-5 parts of fructus amomi, 7-10 parts of endothelium corneum gigeriae galli, 10-15 parts of hawthorn and 7-10 parts of liquorice. The agreement prescription of the internal different prescription has obvious curative effects on improvement of dysmenorrhea symptoms of EMs patients, reduction of tentacle nodules and appendage masses, improvement of pelvic cavity states, increase of pregnancy rates and the like, and is safe and free of obvious toxic and side effects.

Provided is a method and a medicament for treating endometriosis in a subject in need thereof, comprising administering to the subject an effective amount of a sphingosine-1-phosphate receptor 1 (S1PR1) antagonist.

The present disclosure relates to diagnostic and therapeutic applications of photobiomodulation and light therapies such as red-light therapy and electrical stimulation devices. Application areas include gut, uterine and other pelvic conditions, back pain, endometriosis, fibromyalgia, etc. The methods and devices disclosed herein are used for delivering targeted therapy using personalized and adjustable treatment protocols which may use features such as real-time monitoring and closed-loop feedback. The devices described herein can be worn discretely to deliver therapy. The present disclosure also includes artificial intelligence and machine learning-based methods for such diagnostic and therapeutic applications.

A method for treating a noncancerous gynecological disorder comprising: administering to a patient an effective amount of composition comprising a cannabis extract comprising cannabidiol (CBD) wherein the composition is preferably administered in a mucosal form, such as intravaginally.

Methods for diagnosing or monitoring endometriosis in a mammal are provided. The methods include the steps of determining the expression levels of BDNF, glycodelin and optionally ZAG, in a biological sample from the mammal, and determining that the mammal has endometriosis when the biomarker expression levels in the sample are elevated.

The present invention relates to drospirenone for use in a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and / or dysmenorrhea comprising administering drospirenone in a biphasic regimen. The present invention further relates to the use of drospirenone administered in such a biphasic regimen as a contraceptive and for inducing amenorrhea, as well as to pharmaceutical compositions and kits comprising drospirenone administered in such a biphasic regimen.

The present invention relates to injectable microspheres and formulations comprising the microspheres for controlled release of progestogen hormones. The present invention also relates to a method of preparing the microspheres that control the release of the progestogen hormone and methods of using the microspheres that control the release of the progestogen hormone to treat conditions such as pregnancy and fertility in women as well as gynecological disorders such as secondary amenorrhea, endometriosis, abnormal uterine bleeding due to hormonal imbalance, and acne.

Provided are a deuterated tetrahydrothieno[3,4-d]pyrimidinedione compound represented by formula (I) and a pharmaceutical composition containing the compound, or a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof. The compound can be used to treat and / or prevent gonadotropin-releasing hormone (GnRH)-dependent related diseases, such as uterine fibroids, endometriosis, uterine fibroids, amenorrhea, premenstrual syndrome, etc.

The invention discloses a traditional Chinese medicine accurate diagnosis and treatment research platform for endometriosis. The traditional Chinese medicine accurate diagnosis and treatment research platform comprises a cross-mechanism data collaboration interface, a distributed feature extraction engine module and a multi-mode classification decision module, the cross-mechanism data collaboration interface is used for realizing standardized data interaction with an external mechanism; the distributed feature extraction engine module is used for sending the metadata request to an external mechanism and analyzing metadata information returned by the external mechanism; the multi-modal classification decision module is used for classifying analyzed results; the method is characterized in that the metadata request at least comprises the following steps: inputting a data modal specification; the metadata information at least comprises input data modal specifications and all pathological feature data. On the basis of protecting customer privacy, data sharing between external institutions such as hospitals, clinics and research institutions and the system is achieved, so that richer pathological research information is obtained.

In order to prepare the medicine for effectively inhibiting the endometriosis, the invention provides the application of the interleukin 17C blocking agent in preparing the medicine for inhibiting the endometriosis, the interleukin 17C blocking agent is MOR106 and / or a monoclonal antibody which has 90% sequence identity with the MOR106, and the monoclonal antibody has an antigenic determinant corresponding to the interleukin 17C.

The invention belongs to the field of pharmaceutical technology, and relates to sulfonamide-substituted heteroaryl pyrimidine dione compounds and uses thereof, as well as pharmaceutical compositions containing such compounds, which can be used as gonadotropin-releasing hormone receptor antagonists. It also relates to methods for preparing such compounds and pharmaceutical compositions, and their uses in preventing or treating sex hormone-dependent diseases, including but not limited to prostate cancer, endometriosis, uterine fibroids, precocious puberty and the like.

The use of Seawater Pearl Powder in the manufacture of a medicament for treating a woman suffering from menstrual pains and or irregular menstrual symptoms and or endometriosis.

The invention provides application of corydalis saxicola bunting in preparation of anti-angiogenesis drugs. The invention provides application of a corydalis saxicola bunting plant, a traditional Chinese medicinal material of the corydalis saxicola bunting plant or a corydalis saxicola bunting plant extract in preparation of anti-angiogenesis drugs. According to the present invention, the in vivo pharmacodynamic experiment performed by using the zebra fish angiogenesis model for the first time proves that the corydalis saxicola bunting extract can significantly inhibit the angiogenesis of zebra fish, such that the corydalis saxicola bunting extract has the anti-angiogenesis activity, and can be used as the angiogenesis inhibitor, the compound can be applied to treatment of neovascularization-dependent and neovascularization-related diseases such as tumors, arthritis, skin and ophthalmic diseases, atherosclerosis, vascular dementia, endometriosis and the like.

This disclosure belongs to the field of pharmaceutical technology, and specifically relates to the application of targeted proline metabolic enzymes in the treatment of endometriosis. This disclosure, through in vitro experiments and EMS animal models, verifies that the proline content in ectopic endometrial stromal cells increases, the expression of proline synthesis metabolic enzymes is elevated, and fibrosis is significantly activated. This disclosure creatively repurposes proline metabolic enzyme inhibitors for EMS treatment. Proline metabolic enzyme inhibitors specifically inhibit the enzyme activity of key proline metabolism enzymes, blocking the synthesis pathway from glutamate to proline, and directly reducing intracellular proline content. Since proline is a major component amino acid of collagen, the inhibition of proline synthesis directly inhibits collagen synthesis and the expression of fibrosis markers in endometrial stromal cells, ultimately achieving the therapeutic effect of inhibiting fibrosis in EMS ectopic lesions and reducing ectopic lesion growth.

The present invention relates to methods of diagnosing whether a subject has endometriosis, to methods of classifying the stage of endometriosis, to methods of determining the therapeutic effect of a treatment regimen for endometriosis, and methods of monitoring endometriosis progression in a subject, by determining the amount or concentration of c-Kit in a sample of the subject, and comparing the determined level to a reference value.

The invention belongs to the technical field of biological medicine, and discloses application of DON in relieving ovarian fibrosis. The invention discloses an application of DON or a pharmaceutically acceptable derivative thereof in preparation of a medicine for treating or preventing ovarian fibrosis. The invention discloses application of DON in prevention and treatment of ovarian fibrosis, human ovarian is cultured in vitro, DON is added for treatment, and the result shows that DON can reduce the ovarian fibrosis level, so that DON can be used as a potential medicine for recovering female fertility. The DON is prompted to have an obvious promoting effect on recovery of ovarian fibrosis, so that the DON can be used for solving the problems of ovarian fibrosis, non-ovulation and the like caused by endometriosis, and a new medicine choice is provided for clinical treatment of infertility.

The present disclosure relates to a chemogenetic system and method treating endometriosis using a gene therapy vector to deliver a therapeutic payload to specific cells (nociceptive neurons). Overexpression of the payload increases the sensitivity of the cells to an activator, thereby enabling lower doses of activator drugs to be administered. The disclosure also related to vectors to deliver a nucleotide sequence to the target cells to enable overexpression thereof.

This specification describes a pharmaceutical composition of a melatonin receptor agonist for use in tissues outside the CNS. Also described herein are methods of using the pharmaceutical compositions described herein to improve the menopause system and to improve reproductive outcomes in polycystic ovary syndrome, endometriosis, chemotherapy-induced ovarian dysfunction, and inflammatory and metabolic diseases.

In order to prepare a medicine for effectively inhibiting endometriosis, the application provides an application of interleukin 17C blocking agent in preparation of a medicine for inhibiting endometriosis, wherein the interleukin 17C blocking agent is MOR106 and / or a monoclonal antibody with 90% sequence identity with MOR106, and the monoclonal antibody has an antigenic determinant corresponding to interleukin 17C.

The present disclosure relates to a chemogenetic system and method treating endometriosis using a gene therapy vector to deliver a therapeutic payload to specific cells (nociceptive neurons). Overexpression of the payload increases the sensitivity of the cells to an activator, thereby enabling lower doses of activator drugs to be administered. The disclosure also related to vectors to deliver a nucleotide sequence to the target cells to enable overexpression thereof.

The application discloses a kind of endometriosis patient lactation review follow-up data processing system, it is related to medical data processing technical field, the system passes through acquisition patient hospital information, follow-up record, self-report data and equipment monitoring data, and using BERT medical NLP model is carried out vectorization processing to text illness record, standardization storage is realized in combination with NER, and patient data set is arranged according to time sequence;Abnormal data is scored using local anomaly factor and isolation forest algorithm, and provides abnormal data processing strategy;Based on time series analysis and EWMA method, calculate trend change coefficient BQS, monitor the trend of illness change and early warning;Through Euclidean distance, cosine similarity and clustering algorithm analysis patient illness trajectory, calculate similarity score Sxs, judge illness similarity, and provide corresponding strategy to high similarity patient.